Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 110Gynecologic 9Thoracic 5Breast 5Sarcoma 3Genitourinary 3Head & Neck 2CNS 2Other solid neoplasm 1NET 1Endocrine 1Dermatologic 1

Conditions

Neuroendocrine Tumors 2Gastro-enteropancreatic neuroendocrine tumor 2Carcinoma, Ovarian Epithelial 2Stomach Neoplasms 1Sarcoma 1Neoplasms 1Mesothelioma 1Lung Neoplasms 1Glioblastoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Quality of Life 2tislelizumab 1surufatinib 1regorafenib 1lutetium Lu 177 dotatate 1fludarabine phosphate 1fludarabine 1copper dotatate CU-64 1Surveys and Questionnaires 1Poly(ADP-ribose) Polymerase Inhibitors 1Patient Reported Outcome Measures 1PM 01183 1Molecular Diagnostic Techniques 1Magnetic Resonance Spectroscopy 1Lutetium-177 1Lutetium 1Irinotecan 1Immunotherapy 1Fluorodeoxyglucose F18 1FAPI-46 1Drug Therapy 1Cyclophosphamide 1Cryotherapy 1Control Groups 1Clinical Trials, Phase II as Topic 1Biological Therapy 1Betaine 1Acupuncture Therapy 1Acupressure 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × Irinotecan × NET × Clear all
NCT02611024 2025-07-09

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

PharmaMar

Phase 1/2 Completed
316 enrolled
CNSEndocrineGastrointestinalGynecologicNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡